Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2021
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2019
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2018
Area of Science:
Genetics
Molecular Biology
Oncology
Background:
The p53 tumor suppressor gene plays a critical role in preventing cancer.
Genetic variations, such as polymorphisms, can influence p53 function and cancer risk.
The CD 213 (A-G) polymorphism in exon 6 of the p53 gene is of interest due to its potential impact.
Purpose of the Study:
To investigate the frequency of the CD 213 (A-G) polymorphism in the p53 gene within a Turkish population.
To determine if this specific p53 gene polymorphism is associated with an increased risk of developing malignant lymphoma, osteosarcoma, or nasopharyngeal sarcoma.
Main Methods:
Genotyping was performed on DNA samples from a healthy Turkish cohort (n=26) and patients with various tumors (n=21).
Analysis focused on a specific polymorphism located at exon 6 (CD 213) of the p53 gene.
Allele frequencies were compared between healthy individuals and tumor patient groups.
Main Results:
The CD 213 (A-G) polymorphism was found to be extremely rare in the studied Turkish population.
The polymorphic allele was detected in only one individual with malignant lymphoma (4.16% frequency in this subgroup).
No statistically significant association was observed between the CD 213 (A-G) p53 polymorphism and the investigated tumor types.
Conclusions:
The CD 213 (A-G) polymorphism of the p53 gene is of very low frequency in the Turkish population.
Current data suggest that this specific p53 polymorphism is not a significant risk factor for malignant lymphoma, osteosarcoma, or nasopharyngeal sarcoma in this cohort.